CHART in lung cancer: Economic evaluation and incentives for implementation

Radiotherapy and Oncology

Volumn 75, Issue 2, 2005, Pages 171-178

  Lievens, Yolande ^a   Kesteloot, Katrien ^a   Van Den Bogaert, Walter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cost effectiveness; Cost utility; Implementation; Lung cancer; Radiotherapy

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CONTINUOUS HYPERFRACTIONATED AND ACCELERATED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITAL CHARGE; HOSPITAL DEPARTMENT; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RADIATION DOSE FRACTIONATION; SENSITIVITY AND SPECIFICITY; STANDARD; UNIVERSITY HOSPITAL;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; MALE; MODELS, ECONOMIC; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 20444387907     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2005.03.011     Document Type: Article

References (26)

1. B.B. Borgelt, and C. Stone Ambulatory patient classifications and the regressive nature of Medicare Reform: is the reduction in outpatient health care reimbursement worth the price? Int J Radiat Oncol Biol Phys 45 1999 729 734
2. R. Brooks EuroQol: the current state of play Health Policy 37 1996 53 72
3. P. Coy, J. Schaafsma, and J.A. Schofield The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 48 2000 1025 1033
4. D. Coyle, and M.F. Drummond Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus Clin Oncol 9 1997 313 321
5. R.O. Dillman, J. Herndon, and S.L. Seagren Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALBG) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
6. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
7. C.C. Earle, D. Coyle, and W.K. Evans Cost-effectiveness analysis in oncology Ann Oncol 9 1998 475 482
8. W.K. Evans, B.P. Will, and J-M. Berthelot The economics of lung cancer management in Canada Lung Cancer 14 1996 19 29
9. W.K. Evans, B.P. Will, and J-M. Berthelot Cost of combined modality interventions for stage III non-small-cell lung cancer J Clin Oncol 15 1997 3038 3048
10. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
11. P.J. Goodwin, and F.A. Shepherd Economic issues in lung cancer: a review J Clin Oncol 16 1998 3900 3912
12. A. Granados, E. Jonsson, and H.D. Banta EUR-ASSESS Project Subgroup Report on dissemination and impact Int J Technol Assess Health Care 13 1997 220 286
13. L. Jaakkimainen, P.J. Goodwin, and J. Pater Counting the costs of chemotherapy in a national institute of Canada randomised trial in non-small-cell lung cancer J Clin Oncol 8 1990 1301 1309
14. A. Laupacis, D. Feeny, A. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 1992 473 481
15. Y. Lievens, W. Van den Bogaert, and K. Kesteloot Activity-based costing: a practical model for cost calculation in radiotherapy Int J Radiat Oncol Biol Phys 57 2003 522 535
16. P. Marino, A. Preatoni, and A. Cantoni Randomised trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis Cancer 76 1995 593 601
17. Omzendbrief nr. CiRH. 24/535.316 (dd.11.09.2000) van de belastingsadministratie, over de vrijgestelde kilometervergoeding.
18. M.I. Saunders, S. Dische, and A. Barrett Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell lung cancer: mature data from the randomised multicentre trial Radiother Oncol 52 1999 137 148
19. W. Sause, P. Kolesar, and S. Taylor Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer Chest 117 2000 358 364
20. C. Schaake-Koning, W. van den Bogaert, and O. Dalesio Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer N Engl J Med 326 1992 524 530
21. T.J. Smith, B.E. Hillner, and D.M. Neighbonis Economic evaluation of a randomised clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer J Clin Oncol 132 1995 166 173
22. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Desicion Making 13 1993 322 338
23. Sterftetafels, Belgisch Ministerie van Volksgezondheid; 1999.
24. T.O. Tengs, M.E. Adams, and J.S. Pliskin Five-hundred life-saving interventions and their cost-effectiveness Risk Anal 15 1995 369 390
25. T.O. Tengs, and A. Wallace One thousand health-related quality-of-life estimates Med Care 38 2000 583 637
26. B.P. Will, J.M. Berthelot, and K.M. Nobrega Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions Eur J Cancer 37 2001 1797 1804